David Gerber

David Gerber, M.D., serves as Professor in the Department of Internal Medicine at UT Southwestern Medical Center and is a key member of the Division of Hematology and Oncology. He holds the critical leadership position of Co-Director of Education and Training within the Harold C. Simmons Comprehensive Cancer Center, where he shapes educational programs and clinical training initiatives for oncology professionals.

His educational foundation includes a bachelor's degree in history from Yale University (cum laude), medical degree from Cornell University Medical College, internal medicine residency at UT Southwestern (serving as Chief Resident), and advanced fellowship training in medical oncology at Johns Hopkins University School of Medicine. This comprehensive training underpins his dual expertise in clinical care and research leadership.

Dr. Gerber's research program centers on lung cancer therapeutics, with particular emphasis on immunotherapy mechanisms, clinical trial design, and addressing healthcare disparities in safety-net populations. His work consistently bridges laboratory findings with clinical applications, focusing on improving patient quality of life through innovative treatment approaches and accessible screening protocols. Recent investigations explore SARS-CoV-2 interactions with cancer, oncogenic drivers in underserved communities, and novel combination therapies for advanced malignancies.

Analysis of his 273 publications reveals a dominant focus on translational lung cancer research, with significant contributions to immunotherapy safety profiles, biomarker discovery, and health equity initiatives. His work increasingly examines pandemic impacts on cancer care while maintaining strong emphasis on clinical trial methodology and therapeutic innovation across diverse patient populations.

• Best Doctor in Dallas by D Magazine (2011-2023)

As Co-Director of Education and Training, Dr. Gerber oversees curriculum development and mentorship programs within the Cancer Center while actively participating in national oncology education initiatives. His leadership extends to Chairing the Clinical Trials Advisory Committee for the Cancer Prevention and Research Institute of Texas (CPRIT) and serving on the National Comprehensive Cancer Network (NCCN) Oncology Research Program Investigator Steering Committee, where he influences statewide and national clinical trial frameworks. He also contributes to multiple institutional committees at UT Southwestern focused on research integrity and patient care standards.

Dr. Gerber maintains active involvement in professional organizations including the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR), frequently presenting findings at national conferences. His current research integrates artificial intelligence applications in immune-related adverse event management and develops patient-centric clinical trial consent processes, reflecting his commitment to practical innovations in oncology care delivery.